Devil’s Advocate: Skin and Aesthetic Risks of GLP-1 Weight Loss

Conclusions

• GLP-1/GIP receptor agonists provide major metabolic and cardiometabolic benefits, but their use requires careful balancing against dermatologic and body-composition risks.
• Many reported skin and hair adverse effects appear to be associated with rapid weight loss, dose escalation, and nutritional depletion rather than the drugs alone.
• GLP-1-related weight loss can produce visible facial aging, including volume loss, sagging, wrinkles, and the so-called “Ozempic face.”
• Rapid weight loss may also reduce dermal collagen, elastin, fibroblast activity, and skin thickness, weakening structural support and barrier function.
• Muscle and lean mass loss are important concerns because loss of structural support can worsen skin laxity and contribute to sarcopenia.
• Dermal white adipose tissue likely plays a key role in facial, hair, and skin integrity, and GLP-1 signaling may reduce this tissue independent of overall fat loss.
• Hair loss, especially telogen effluvium, and other cutaneous adverse events are plausible and increasingly reported with GLP-1/GIP therapies.
• The dermatologic effects of GLP-1/GIP therapy are multifactorial and should be minimized through slower weight loss, adequate protein and micronutrient intake, and resistance training.
• Patients who develop aesthetic or skin changes after GLP-1 use may require multimodal dermatologic or cosmetic management, including volume restoration and collagen-stimulating treatments.
• Overall, the presentation argues that GLP-1/GIP therapy should be individualized, with ongoing monitoring to preserve muscle, nutrition, and skin health while achieving weight-loss benefits.